CG Oncology, Inc.
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
There are no news to display.
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, February 27, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of Mar 23 and 27 (est)
Price History
Beta
--
7-Day Total Return
--
30-Day Total Return
--
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
--
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
-- - --
52-week High
-- - --
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
--
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
949 409 3700
Address
400 Spectrum Center Drive
Irvine, CA 92618
Irvine, CA 92618
Country
Year Founded
Business Description
Sector
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s...
more